Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report

Journal of Hepatology

Volumn 55, Issue 5, 2011, Pages 1121-1131

  Chan, Henry Lik Yuen ^a   Thompson, Alex ^b   Martinot Peignoux, Michelle ^c   Piratvisuth, Teerha ^d   Cornberg, Markus ^e   Brunetto, Maurizia Rossana ^f   Tillmann, Hans L ^g   Kao, Jia Horng ^h   Jia, Ji Dong ⁱ   Wedemeyer, Heiner ^e   Locarnini, Stephen ^b   Janssen, Harry L A ^j   Marcellin, Patrick ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^d PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF PISA   (Italy)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Antiviral treatment; HBsAg; Hepatitis B virus; Peginterferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CIRCULAR DNA; ENTECAVIR; GENOMIC RNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL PRACTICE; CODON; DISEASE CARRIER; DISEASE COURSE; DRUG EFFICACY; ENZYME IMMUNOASSAY; GENOTYPE; HEPADNAVIRUS INFECTION; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; LIVER CELL; LIVER CIRRHOSIS; MINICHROMOSOME; NONHUMAN; OPEN READING FRAME; PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT RESPONSE; VIREMIA; VIRION; VIRUS DNA CELL DNA INTERACTION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 80054724912     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.06.006     Document Type: Review

References (85)

1. B.S. Blumberg, A.I. Sutnick, and W.T. London Hepatitis and leukemia: their relation to Australia antigen Bull NY Acad Med 44 1968 1566 1586
2. G.G. Frosner, H. Schomerus, and K.H. Wiedmann Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection Eur J Clin Microbiol 1 1982 52 58 (Pubitemid 12025122)
3. M. Deguchi, N. Yamashita, and M. Kagita Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay J Virol Methods 115 2004 217 222 (Pubitemid 37506037)
4. F. Bonino, M.R. Brunetto, P. Colombatto, F. Moriconi, E. Torresani, and G. Lunghi Use of the Elecysys HBsAg II assay for simple and accurate quantification of HBsAg levels in sera of patients infected with HBV Hepatol Int 3 2009 108
5. B. Werle-Lapostolle, S. Bowden, and S. Locarnini Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758 (Pubitemid 38736340)
6. H.L. Chan, V.W. Wong, and A.M. Tse Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 2007 1462 1468 (Pubitemid 350181604)
7. G.C. Kimbi, A. Kramvis, and M.C. Kew Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B World J Gastroenterol 11 2005 6416 6421 (Pubitemid 43136875)
8. C.A. Bill, and J. Summers Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration Proc Natl Acad Sci USA 101 2004 11135 11140 (Pubitemid 38989596)
9. H.C. Thomas, and S.M. Lemon Viral hepatitis 3rd ed. 2005 Blackwell Publishing Massachusetts, USA
10. T. Nguyen, A.J. Thompson, and S. Bowden Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia J Hepatol 52 2010 508 513
11. J. Jaroszewicz, B. Calle Serrano, and K. Wursthorn Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective J Hepatol 52 2010 514 522
12. A.J. Thompson, T. Nguyen, and D. Iser Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers Hepatology 51 2010 1933 1944
13. L.Y. Lin, V.W. Wong, and H.J. Zhou Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients J Med Virol 82 2010 1494 1500
14. T. Volz, M. Lutgehetmann, and P. Wachtler Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients Gastroenterology 133 2007 843 852 (Pubitemid 47374140)
15. N. Warner, and S. Locarnini The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound Hepatology 48 2008 88 98 (Pubitemid 351975534)
16. N. Warner, and S. Locarnini Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma? Antivir Ther 14 2009 139 142
17. F. Bonino, F. Moriconi, and S. Bowden Multicenter evaluation of the Elecsys HBsAg II Quant Assay Hepatol Int 5 2011 80
18. Sonneveld MJ, Rijckborst V, Boucher CAB, et al. A comparison of two assays for quantification of hepatitis B surface antigen in serum of patients with chronic hepatitis B. J Hepatol 2011;54:Abstract 750.
19. K. Wursthorn, J. Jaroszewicz, and B.J. Zacher Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum J Clin Virol 50 2011 292 296
20. H.L. Chan, G.L. Wong, and V.W. Wong A review of the natural history of chronic hepatitis B in the era of transient elastography Antivir Ther 14 2009 489 499
21. M. Sugiyama, T. Tasuhito, and T. Kato Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens Hepatology 44 2006 915 924 (Pubitemid 46489556)
22. H.L. Chan, V.W. Wong, G.L. Wong, C.H. Tse, H.Y. Chan, and J.J. Sung A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B Hepatology 52 2010 1232 1241
23. Cheng PN, Tsai HW, Chang TT. Serum hepatitis B surface antigen level is associated with liver fibrosis in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2011;54:Abstract 362.
24. G.L. Wong, V.W. Wong, and P.C. Choi Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B Clin Gastroenterol Hepatol 7 2009 227 233
25. G.B. Gaeta, G. Stornaiuolo, and D.F. Precone Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study J Hepatol 39 2003 1036 1041 (Pubitemid 37523777)
26. S. Hadziyannis, and G.V. Papatheodoridis Hepatitis B e antigen-negative chronic hepatitis: natural history and treatment Semin Liver Dis 26 2006 130 141 (Pubitemid 43668255)
27. J.P. Zarski, P. Marcellin, and V. Leroy Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases J Hepatol 45 2006 355 360 (Pubitemid 44160628)
28. M.R. Brunetto, F. Oiveri, and B. Coco Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon and untreated patients: a long term cohort study J Hepatol 36 2002 263 270 (Pubitemid 34146434)
29. J.J. Sung, H.L. Chan, and M.L. Wong Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients J Viral Hepat 9 2002 229 234 (Pubitemid 36005522)
30. M. Martinot-Peignoux, N. Boyer, and M. Colombat Serum hepatitis B virus HBV DNA levels and liver histology in inactive HBsAg carriers J Hep 36 2002 543 546 (Pubitemid 34407344)
31. M.R. Brunetto, F. Oliveri, and G. Rocca Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen Hepatology 10 1989 198 202 (Pubitemid 19190211)
32. G.V. Papatheodoridis, E.K. Manesis, and S. Manalakopoulos Is there a meaninful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B infection? Hepatology 48 2008 1451 1459
33. B.J. McMahon The natural history of chronic hepatitis B virus infection Hepatology 49 2009 S45 S55
34. A.S. Lok, E.J. Heathcote, and J.H. Hoofnagle Management of hepatitis B: 2000 - summary of a workshop Gastroenterology 120 2001 1828 1853 (Pubitemid 32523500)
35. EASL clinical practice guidelines: management of chronic hepatitis B. European Association for the Study of the Liver. J Hepatol 2009;50:227-242.
36. C.J. Chu, M. Hussain, and A.S.F. Lik Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection Hepatology 36 2002 1408 1415 (Pubitemid 35407438)
37. Y. Seo, S. Yoon, and B.X. Truong Serum HBV DNA levels differentiating inactive carriers from patients with chronic hepatitis B Eur J Gastroenterol Hepatol 17 2005 753 757 (Pubitemid 40896422)
38. J.J. Feld, M. Ayers, and D. El-Ashry Hepatitis B virus DNA prediction rules for Hepatitis B e antigen-negative chronic hepatitis B Hepatology 46 2007 1070 1507
39. H.L. Chan, G.L. Wong, C.H. Tse, H.Y. Chan, and V.W. Wong Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients J Infect Dis 204 2011 408 414
40. T.H. Su, C.S. Hsu, and C.L. Chen Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B Antivir Ther 15 2010 1133 1139
41. Tseng TC, Liu CJ, Su TH, et al. Serum Hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology, 2011[Epub ahead of print].
42. M.R. Brunetto, F. Oliveri, and P. Colombatto Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers Gastroenterology 139 2010 483 490
43. M. Martinot-Peignoux, O. Lada, and A.C. Cardoso Quantitative HBsAg: A new specific marker for the diagnosis of HBsAg inactive carriage Hepatology 52 2010 992A
44. Yakut M, Bektas M, Seven G, et al. Characterization of the inactive HBsAg carrier state with 3 year follow-up. J Hepatol 2011;54:Abstract 398.
45. Jang JW, Yoo SH, Ho BS, et al. Distribution patterns of serum hepatitis B surface antigen levels over the natural course of chronic hepatitis B: the role of age and immune phase. J Hepatol 2011;54:Abstract 373.
46. K. Wursthorn, M. Lutgehetmann, and M. Dandri Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 2006 675 684 (Pubitemid 44433724)
47. V.W. Wong, G.L. Wong, and K.K. Yan Durability of Peginterferon alfa-2a treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 1945 1953
48. H.L.A. Janssen, C.J. Kerhof-Los, R.A. Heijtink, and S.W. Schalm Measurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy Antivir Res 23 1994 251 257 (Pubitemid 24122302)
49. H.L. Chan, V.W. Wong, and A.M. Chim Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B Aliment Pharmacol Ther 32 2010 1323 1325
50. P. Tangkijvanich, P. Komolmit, and V. Mahachai Low pretreatment serum HBsAg level and viral mutations as predictors of response to Peginterferon alfa-2b therapy in chronic hepatitis B J Clin Virol 46 2009 117 123
51. G. Lau, P. Marcellin, and M. Brunetto On treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B J Hepatol 50 2009 S333
52. Gane E, Jia J, Han K, et al. NEPTUNE study: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients. J Hepatol 2011;54:Abstract 69.
53. M.J. Sonneveld, V. Rijckborst, C.A. Boucher, B.E. Hansen, and H.L. Janssen Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline Hepatology 52 2010 1251 1257
54. T. Piratvisuth, and P. Marcellin Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all HBeAg-positive patients Hepatology 53 2011 1054 1055
55. M.R. Brunetto, F. Moriconi, and F. Bonino Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
56. M.R. Brunetto, F. Bonino, and P. Marcellin Kinetic of HBsAg decline in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a according to genotype and its association with sustained HBsAg clearance 4 years post treatment Hepatology 48 4 2008 965A [Abstract]
57. M.R. Brunetto, D. Cavallone, and F. Moriconi Kinetics of HBsAg decline during and following treatment of CHB: early and rapid HBsAg decline during peginterferon-2a in predictive of HBsAg clearance Hepatology 48 4 2008 717A [Abstract]
58. F. Bonino, P. Marcellin, and G.K. Lau Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut 56 2007 699 705 (Pubitemid 46662938)
59. Takkenberg B, Zaaijer HL, De Niet A, et al. Baseline HBsAg level and on-treatment HBsAg and HBV DNA decline predict sustained virological response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a (Pegasys) and Adefovir (Hepsera); an interim analysis. Hepatology 2009;50:Abstract 491.
60. V. Rijckborst, B.E. Hansen, and Y. Cakaloglu Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels Hepatology 52 2010 454 461
61. R. Moucari, V. Mackiewicz, and O. Lada Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
62. V. Rijckborst, M.J. Ter Borg, and Y. Cakaloglu A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B Am J Gastroenterol 105 2010 1762 1769
63. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-79 [e1-4].
64. P. Marcellin, G.K. Lau, and F. Bonino Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217 (Pubitemid 39296307)
65. P. Marcellin, T. Piratvisuth, and M. Brunetto On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment, subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a Hepatol Int 4 2010 151
66. Rijckborst V, Hansen B, Ferenci P, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy. Hepatology 2010;52:Abstract 479.
67. R. Moucari, M. Martinot-Peignoux, and V. Mackiewicz Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a Antivir Ther 14 2009 1183 1188
68. M.R. Brunetto, F. Moriconi, and F. Bononi Hepatitis B virus surface antigen levels: a guide to sutained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
69. M. Kohmoto, M. Enomoto, and A. Tamori Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers J Med Virol 75 2005 235 239 (Pubitemid 40053734)
70. E.K. Manesis, E.S. Hadziyannis, O.S. Angelopoulou, and S.J. Hadziyannis Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 2007 73 82 (Pubitemid 46340428)
71. J. Wiegand, H. Wedemeyer, and A. Finger A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels Antivir Ther 13 2008 547 554 (Pubitemid 352016717)
72. O. Borgniet, P. Parvaz, and C. Bouix Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B J Med Virol 81 2009 1336 1342
73. K. Wursthorn, M. Jung, and A. Riva Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
74. W. Cai, Q. Xie, and B. An On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients J Clin Virol 48 2010 22 26
75. J.G. Reijnders, V. Rijckborst, and M.J. Sonneveld Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir J Hepatol 54 2011 449 454
76. Zoutendijk R, Hansen BE, Van Vuuren AJ, Boucher CA, Janssen HL. Prediction of HBsAg loss using HBsAg decline after long-term virological response to nucleos(t)ide analogue therapy for chronic hepatitis B. Hepatology 2010;52:Abstract 381.
77. Chevaliez S, Hezode C, Grare M, Pawlotsky JM. Long-term monitoring of HBsAg kinetics and prediction of HBsAg clearance in patients with chronic hepatitis B treated with nucleoside/nucleotide analogues. Hepatology 2010;52:Abstract 374.
78. Jaroszewicz J, Ho H, Deterding K, et al. Prediction of HBsAg loss by quantitative HBsAg kinetics during long-term treatment with nucleos(t)ide analogues. Hepatology 2010;52:Abstract 395.
79. E.J. Heathcote, P. Marcellin, and M. Buti Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
80. Marcellin P, Heathcote EJ, Buti M, et al. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol 2011;54:Abstract 740.
81. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW. Serum HBsAg quantification can predict sustained response to lamivudine in patients with negative HBeAg: a long-term post-treatment study. Hepatol Int 2011;5:Abstract PP05-102.
82. Jiang NJ, Liang XY, Su HM, et al. Study of influence factors on HBV relapse after NAS withdrawal in the CHB patients who met NAS cessation criteria. J Hepatol 2011;54:Abstract 722.
83. Manesis EK, Papatheodoridis GV, Hadziyannis E. Significance of serum HBsAg levels for the definition of the inactive hepatitis B carrier. Hepatology 2010;52:Abstract 483.
84. Verheyen J, Neumann-Fraune M, Berg T, Kaiser R, Obermeier M. Mutations in the HBs-antigen influence the results of HBsAg quantification assays. J Hepatol 2011;54:Abstract 394.
85. Bruce M, Horner M, Shang D, et al. Mutation RTA181T/SW172 is associated with lower HBsAg levels than other mutations in HBV polymerase codon 181 an overlapping surface codon 172 - implications for vaccination? J Hepatol 2011:54:Abstract 706.